Effect of the Rho kinase inhibitor Y-27632 on the proteome of hearts with ischemia-reperfusion injury

Proteomics

Volumn 10, Issue 24, 2010, Pages 4377-4385

  Cadete, Virgilio J J ^a   Sawicka, Jolanta ^a   Polewicz, Dorota ^a   Doroszko, Adrian ^a,b   Wozniak, Mieczyslaw ^b   Sawicki, Grzegorz ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Animal proteomics; Ischemia reperfusion; Metabolic enzymes; Pharma coproteomics; Rho kinase; Y 27632

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LACTATE DEHYDROGENASE; PEROXIREDOXIN 3; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; RAT; REPERFUSION INJURY; TWO DIMENSIONAL ELECTROPHORESIS;

AMIDES; AMINO ACID SEQUENCE; ANIMALS; MALE; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MOLECULAR SEQUENCE DATA; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTEIN KINASE INHIBITORS; PROTEIN SUBUNITS; PROTEOME; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES;

ANIMALIA; RATTUS;

EID: 78650068857     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000393     Document Type: Article

References (29)

1. Alpert, J. S., Thygesen, K., Jaffe, A., White, H. D., The universal definition of myocardial infarction: a consensus document: ischaemic heart disease. Heart 2008, 94, 1335-1341.
2. Roger, V. L., Severity of myocardial infarction: new insights on an elusive construct. Circulation 2009, 119, 489-491.
3. Van de Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C. et al., Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur. Heart J. 2008, 29, 2909-2945.
4. Zhou, Q., Liao, J. K., Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr. Pharm. Des. 2009, 15, 3108-3115.
5. Shimokawa, H., Takeshita, A., Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1767-1775.
6. Amano, M., Chihara, K., Kimura, K., Fukata, Y. et al., Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997, 275, 1308-1311.
7. Yasui, Y., Amano, M., Nagata, K., Inagaki, N. et al., Roles of Rho-associated kinase in cytokinesis; mutations in Rho-associated kinase phosphorylation sites impair cytokinetic segregation of glial filaments. J. Cell Biol. 1998, 143, 1249-1258.
8. Majumdar, M., Seasholtz, T. M., Goldstein, D., de Lanerolle, P., Brown, J. H., Requirement for Rho-mediated myosin light chain phosphorylation in thrombin-stimulated cell rounding and its dissociation from mitogenesis. J. Biol. Chem. 1998, 273, 10099-10106.
9. Wolfrum, S., Dendorfer, A., Rikitake, Y., Stalker, T. J. et al., Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1842-1847.
10. Hamid, S. A., Bower, H. S., Baxter, G. F., Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am. J. Physiol. 2007, 292, H2598-H2606.
11. Uehata, M., Ishizaki, T., Satoh, H., Ono, T. et al., Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389, 990-994.
12. Kobayashi, N., Horinaka, S., Mita, S., Nakano, S. et al., Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc. Res. 2002, 55, 757-767.
13. Davies, S. P., Reddy, H., Caivano, M., Cohen, P., Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
14. Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R. et al., ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004, 110, 588-636.
15. Cheung, P. Y., Sawicki, G., Wozniak, M., Wang, W. et al., Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000, 101, 1833-1839.
16. Sawicki, G., Leon, H., Sawicka, J., Sariahmetoglu, M. et al., Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005, 112, 544-552.
17. Fert-Bober, J., Basran, R. S., Sawicka, J., Sawicki, G., Effect of duration of ischemia on myocardial proteome in ischemia/reperfusion injury. Proteomics 2008, 8, 2543-2555.
18. Sawicki, G., Dakour, J., Morrish, D. W., Functional proteomics of neurokinin B in the placenta indicates a novel role in regulating cytotrophoblast antioxidant defences. Proteomics 2003, 3, 2044-2051.
19. Sawicki, G., Jugdutt, B. I., Detection of regional changes in protein levels in the in vivo canine model of acute heart failure following ischemia-reperfusion injury: functional proteomics studies. Proteomics 2004, 4, 2195-2202.
20. Perkins, D. N., Pappin, D. J., Creasy, D. M., Cottrell, J. S., Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20, 3551-3567.
21. Bao, W., Hu, E., Tao, L., Boyce, R. et al., Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc. Res. 2004, 61, 548-558.
22. Scolletta, S., Biagioli, B., Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Biomed. Pharmacother. 2010, 64, 203-207.
23. Dyck, J. R., Lopaschuk, G. D., AMPK alterations in cardiac physiology and pathology: enemy or ally?. J. Physiol. 2006, 574, 95-112.
24. Armstrong, S. C., Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc. Res. 2004, 61, 427-436.
25. Hill, C. S., Treisman, R., Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995, 80, 199-211.
26. Whitmarsh, A. J., Davis, R. J., Regulation of transcription factor function by phosphorylation. Cell. Mol. Life Sci. 2000, 57, 1172-1183.
27. Stanley, W. C., Recchia, F. A., Lopaschuk, G. D., Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005, 85, 1093-1129.
28. Jullig, M., Hickey, A. J., Chai, C. C., Skea, G. L. et al., Is the failing heart out of fuel or a worn engine running rich? A study of mitochondria in old spontaneously hypertensive rats. Proteomics 2008, 8, 2556-2572.
29. Friess, U., Stark, M., Cardiac markers: a clear cause for point-of-care testing. Anal. Bioanal. Chem. 2009, 393, 1453-1462.